Currently, nuclear theranostics is used in the treatment of neuroendocrine tumors (NETs) with the use of 68Ga/177Lu-DOTA-peptides as well as in prostate carcinoma with 68Ga/18F-PSMA and 177Lu/225Ac-PSMA ligands. Here, FOLH1 is linked to neuroendocrine neoplasm.